---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-103527"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T18:58:39.800054+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# EyePoint Q2 net loss $59.4M; completes Phase 3 enrollment for DURAVYU in wet AMD

## Summary
- Net revenue $5.3M, down from $9.5M YoY; net loss $59.4M ($0.85/share) vs. $30.8M ($0.58/share) in Q2 2024.
- Total operating expenses $67.6M, up from $44.0M, driven by DURAVYU Phase 3 trial costs.
- Cash, equivalents and marketable securities $256M as of June 30, 2025; cash runway into 2027.
- Completed enrollment in both Phase 3 wet AMD trials (LUGANO and LUCIA) with over 800 patients; topline LUGANO data mid-2026.
- Initiated DURAVYU registration batches at Northbridge, MA commercial manufacturing facility.

## SEC filing metadata
- accession: 0000950170-25-103527
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017025103527/0000950170-25-103527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017025103527/eypt-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-103527
- JSON: https://secwatch.observer/filing/0000950170-25-103527.json
- Plain text: https://secwatch.observer/filing/0000950170-25-103527.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.